Manufacturer: Zydus Cadila
Pharmaceutical name: Ethinylestradiol, Desogestrel
Pack: 21 pills (0.02 mg / 0.1 mg)
Oral contraceptives, commonly known as birth control pills, are utilized to prevent pregnancy. They modify the uterine lining to inhibit the development of a pregnancy and alter the cervical mucus to block sperm from entering the uterus.
Ethinylestradiol is employed in contraception, the treatment of post-menopausal osteoporosis, hormone replacement therapy (HRT), addressing ovarian developmental issues, and managing prostate cancer.
Ethinylestradiol is part of a group of medications referred to as estrogens (female hormones). This synthetic version of the naturally occurring hormone facilitates the regulation and upkeep of the menstrual cycle. In women who are post-menopausal, it alleviates symptoms associated with menopause and lowers the risk of bone density loss and fractures.
Typical side effects include: nausea, vomiting, swelling, stomach pain, changes in libido, breast tenderness, breast discomfort, burning sensations, constipation, depression, menstrual pain, gas, hair loss, headaches, heartburn, emotional fluctuations, skin rashes, skin redness, vaginal burning, abnormal vaginal discharge, weight loss, and weight gain.
Desogestrel is a type of progestogen, a female sex hormone, that works by inhibiting the maturation of the egg cell. Ethinylestradiol is also used in the contexts of contraception, post-menopausal osteoporosis, hormone replacement therapy, ovarian developmental failure, and prostate cancer.
Side effects frequently reported include: nausea, ovarian cysts, pain, skin masses, acne, breast discomfort, unusual milky breast discharge, breast secretions, decreased libido, issues with contact lenses, menstrual pain, hair loss, headaches, missed menstrual periods, irregular cycles, mood changes, hives, vaginal infections, vomiting, fatigue, and weight gain.
Research involving animals or humans has revealed fetal abnormalities and/or there is substantial evidence of human fetal risk based on adverse reaction data from research or marketing experience, indicating that the risks associated with the drug's use in pregnant women far outweigh any potential benefits.